Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Starts China Trial of Tumor Treating Fields Device for Gastric Cancer

publication date: Jan 9, 2020

Shanghai's Zai Lab has begun enrolling patients in a China Phase II trial of Optune®, its Tumor Treating Fields device, in combination with chemotherapy to treat gastric adenocarcinoma. The TTF technology is a wearable device that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cell death. Previously, Zai has filed for China approval of the technology as a treatment for glioblastoma multiforme. In 2018, Zai paid $15 million upfront to in-license greater China rights for the Optune device from Novocure of Jersey. More details....

Stock Symbols: (NSDQ: ZLAB) (NSDQ: NVCR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.